Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Issue 7 (1st December 2016)

• Record Type: Journal Article
• Authors: Ananth, Prasanna; Werger, Annette; Voss, Stephan; Rodriguez‐Galindo, Carlos; Janeway, Katherine A.
• Is Part Of: Pediatric blood & cancer. Volume 64:Issue 7(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2016-12-01
• Subjects: desmoid fibromatosis -- liposomal doxorubicin -- pediatric -- progression‐free interval -- RECIST; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.26375
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.